Cargando…

Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13)

SARS-CoV-2 has caused COVID-19 outbreak with nearly 2 M infected people and over 100K death worldwide, until middle of April 2020. There is no confirmed drug for the treatment of COVID-19 yet. As the disease spread fast and threaten human life, repositioning of FDA approved drugs may provide fast op...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ugurel, Osman Mutluhan, Mutlu, Ozal, Sariyer, Emrah, Kocer, Sinem, Ugurel, Erennur, Inci, Tugba Gul, Ata, Oguz, Turgut-Balik, Dilek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7513821/ https://www.ncbi.nlm.nih.gov/pubmed/32980406 http://dx.doi.org/10.1016/j.ijbiomac.2020.09.138

Ejemplares similares

An updated analysis of variations in SARS-CoV-2 genome
por: UGUREL, Osman Mutluhan, et al.
Publicado: (2020)

Genomic chronicle of SARS-CoV-2: a mutational analysis with over 1 million genome sequences
por: UĞUREL, Osman Mutluhan, et al.
Publicado: (2021)

An insight into the epitope-based peptide vaccine design strategy and studies against COVID-19
por: TOPUZOĞULLARI, Murat, et al.
Publicado: (2020)

In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors
por: Gurung, Arun Bahadur
Publicado: (2020)

Mitoxantrone dihydrochloride, an FDA approved drug, binds with SARS-CoV-2 NSP1 C-terminal
por: Kumar, Prateek, et al.
Publicado: (2022)

Screening of FDA-approved compound library identifies potential small-molecule inhibitors of SARS-CoV-2 non-structural proteins NSP1, NSP4, NSP6 and NSP13: molecular modeling and molecular dynamics studies
por: Sundar, Shobana, et al.
Publicado: (2021)

Targeting the nsp2 Cysteine Protease of Chikungunya Virus Using FDA Approved Library and Selected Cysteine Protease Inhibitors
por: Kumar, Prateek, et al.
Publicado: (2019)

ATPase and helicase activities of porcine epidemic diarrhea virus nsp13
por: Ren, Jie, et al.
Publicado: (2021)

Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs
por: Cerón-Carrasco, José Pedro
Publicado: (2020)

Ligand and Structure-Based In Silico Determination of the Most Promising SARS-CoV-2 nsp16-nsp10 2′-o-Methyltransferase Complex Inhibitors among 3009 FDA Approved Drugs
por: Eissa, Ibrahim H., et al.
Publicado: (2022)

The nsp15 Nuclease as a Good Target to Combat SARS-CoV-2: Mechanism of Action and Its Inactivation with FDA-Approved Drugs
por: Saramago, Margarida, et al.
Publicado: (2022)

Cooperative Activity of SARS Coronavirus Nsp13 Helicase Characterized by Single Molecule FRET
por: Im, Hyeryeon, et al.
Publicado: (2015)

An immunoinformatics approach to study the epitopes of SARS-CoV-2 helicase, Nsp13
por: Kumar, Sushant, et al.
Publicado: (2023)

Angiotensin (1−7) peptide replacement therapy with plasma transfusion in COVID-19
por: Onal, Hasan, et al.
Publicado: (2022)

Translatability of in vitro potency to clinical efficacious exposure: A retrospective analysis of FDA‐approved targeted small molecule oncology drugs
por: Kotani, Naoki, et al.
Publicado: (2023)

Editorial: Women in skin cancer vol II: 2022
por: Ugurel, Selma, et al.
Publicado: (2023)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Cooperative translocation enhances the unwinding of duplex DNA by SARS coronavirus helicase nsP13
por: Lee, Na-Ra, et al.
Publicado: (2010)

Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase
por: White, Mark Andrew, et al.
Publicado: (2020)

Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13
por: Yu, Mi-Sun, et al.
Publicado: (2012)

Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase
por: Newman, Joseph A., et al.
Publicado: (2021)

Force-dependent stimulation of RNA unwinding by SARS-CoV-2 nsp13 helicase
por: Mickolajczyk, Keith J., et al.
Publicado: (2021)

Force-Dependent Stimulation of RNA Unwinding by SARS-CoV-2 NSP13 Helicase
por: Mickolajczyk, Keith J., et al.
Publicado: (2021)

Molecular dynamics simulations of the flexibility and inhibition of SARS-CoV-2 NSP 13 helicase
por: Raubenolt, Bryan A., et al.
Publicado: (2022)

The stalk domain of SARS-CoV-2 NSP13 is essential for its helicase activity
por: Yue, Kun, et al.
Publicado: (2022)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
por: Utikal, Jochen, et al.
Publicado: (2007)

In Silico Insights towards the Identification of SARS-CoV-2 NSP13 Helicase Druggable Pockets
por: Ricci, Federico, et al.
Publicado: (2022)

Z-RNA and the Flipside of the SARS Nsp13 Helicase: Is There a Role for Flipons in Coronavirus-Induced Pathology?
por: Herbert, Alan, et al.
Publicado: (2022)

A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance
por: Grimes, Samantha L., et al.
Publicado: (2023)

Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies
por: Rodriguez, Ismael, et al.
Publicado: (2023)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

The attitudes of fertile and infertile women to Oocyte donation in a Muslim and Secular population
por: Aslan, Mehmet Musa, et al.
Publicado: (2017)

SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts
por: Shu, Ting, et al.
Publicado: (2020)

Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase
por: Zeng, Jingkun, et al.
Publicado: (2021)

Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro
por: Lu, Lian, et al.
Publicado: (2022)

In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity
por: Mohammad, Thahani S. Habeeb, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e413nlgfbmlf5ptqh49j4vr3ad